伊贝沙坦与依那普利联合治疗慢性充血性心力衰竭的临床疗效

目的:观察伊贝沙坦与依那普利联合治疗慢性充血性心力衰竭(CHF)的临床疗效。方法:选择CHF患者87例,随机分成2组:对照组(n=43)在常规治疗基础上加用依那普利;治疗组(n=44)在常规治疗基础上加用伊贝沙坦与依那普利。结果:疗程结束时,与对照组比较,治疗组的心功能、左室射血分数(LVEF)、左室舒张末期内径(LVDd)、左室收缩末期内径(LVDs)、左室减速时间,P均<0.05,药物不良反应(咳嗽、皮疹、低血压、头晕)发生率2组比较,P>0.05。结论:依那普利与伊贝沙坦联合治疗CHF较单用依那普利疗效好,且安全。

Clinical observation of the application of irbesartan and enalapril in treatment of congestive heart failure

AIM: To observe the clinical curative effect of irbesartan and enalapril on congestive heart failure (CHF). METHODS: Eighty-seven cases were selected and randomly divided into 2 groups: the group of contrast (43 cases) and the group of treatment observation (44 cases) according to the situation of treatment. For the former, enalapril was solely applied on the basis of regular treatment. For the latter, both enalapril and irbesartan were appplied on the basis of regular treatment. RESULTS: There was significant difference in heart function, left ventricular ejection fraction (LVEF), left ventricular end diastolic dimension (LVDd) , left ventricular end systolic dimension (LVDs) and decrease time compared with the group of contrast (P < 0.05) . The adverse drug reactions such as cough, low blood pressure, rash and dizziness did not show any differences compared with the group of contrast (P > 0.05) . CONCLUSION: It's much better and safer to apply enalapril and irbesartan in the treatment of CHF.